{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-163990","form_type":"8-K","ticker":"VOR","cik":"0001817229","company_name":"Vor Biopharma Inc.","filed_at":"2023-06-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.809905+00:00","generated_at":"2026-06-14T04:10:58.797158+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vor Bio reports engraftment data from 5 AML patients in trem-cel study; FDA clears VCAR33 ALLO IND","bullets":["All 5 trem-cel patients achieved neutrophil engraftment in 10-11 days; high myeloid donor chimerism at day 28.","Patient 2 had secondary graft failure coincident with coronavirus hKU1 and antimicrobials; backup graft restored engraftment.","Patient 3 has recovering platelets with autoimmune thrombocytopenia; count 15,000/µL independent of transfusions.","Patients 4 and 5 had normal engraftment and recovery with no unexpected adverse events; cell doses met release criteria.","FDA cleared IND for VCAR33 ALLO (allogeneic CAR-T targeting CD33); VBP301 trial to focus on relapsed post-allo-SCT patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-163990","json":"https://secwatch.observer/filing/0001193125-23-163990.json","markdown":"https://secwatch.observer/filing/0001193125-23-163990.md","text":"https://secwatch.observer/filing/0001193125-23-163990.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817229/000119312523163990/0001193125-23-163990-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817229/000119312523163990/d623996d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T04:10:58.797158+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}